HOWARU® La-14® HOWARU® La-14® Lactobacillus acidophilus La-14® Image credits: © IFF, Finland, 2021 (FESEM imaging VTT) HOWARU® Lactobacillus acidophilus La-14® is a lactic acid bacterium of human origin that has been documented in over 115 scientific studies, including more than 35 clinical trial publications. Product Information: ~ 59 preclinical publications 35+ clinical publications Health Benefits: ImmuneWomen's La-14® BLENDS Learn more about IFF Health Sciences’ La-14® blends. HOWARU® Feminine Health HOWARU® Protect Prenatal + La-14® CLINICAL STUDIES & PUBLICATIONS Preclinical studies have shown La-14® can impact both the innate and the adaptive immune system.¹ These effects and antipathogenic activity are thought to be potential mechanisms behind the efficacy of La-14® combined with HN001™ for intimate health (HOWARU® Protect Prenatal+ and HOWARU® Feminine Health) as well as women’s health.² ³ In addition, these two strains together have been shown to support healthy vaginal colonization and microbiota through oral supplementation.⁴ Health Benefit Areas Each strain’s health benefits are supported by recommended daily doses and peer-reviewed clinical studies. Click on a Health Benefit to see more studies and learn more. Immune Health Supporting Daily Dose: 6B CFU HN001™, 9B CFU La-14® Study Reference: Wickens K, et al. BJN. 2017;117(6):804-813.* Slykerman RF, et al. EBioMedicine. 2017;24:159-165. * Regional restrictions apply, please connect with your account manager for further information. LEARN MORE References: 1. Elawadli I et al.;Beneficial Microbes. 2014; 2. Bertuccini L et al.; Intl J Immunopathology Pharmacology. 2017; 3. Jang SE et al.;Nutrients. 2017; 4. De Alberti D et al.. Arch Gynecol Obstet. 2015